These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30210632)

  • 21. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
    Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour.
    Pine JK; Morris E; Hutchins GG; West NP; Jayne DG; Quirke P; Prasad KR
    Br J Cancer; 2015 Jul; 113(2):204-11. PubMed ID: 26125452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients.
    Jin M; Wu J; Shi L; Zhou B; Shang F; Chang X; Dong X; Deng S; Liu L; Cai K; Nie X; Zhang T; Fan J; Liu H
    Front Microbiol; 2022; 13():993285. PubMed ID: 36312959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
    Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
    Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
    Liao CK; Lin YC; Hsu YJ; Chern YJ; You JF; Chiang JM
    Hered Cancer Clin Pract; 2021 Jun; 19(1):29. PubMed ID: 34187536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
    Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
    Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
    Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
    Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
    Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
    Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression status of four mismatch repair proteins in patients with colorectal cancer: clinical significance in 1238 cases.
    Chen L; Chen G; Zheng X; Chen Y
    Int J Clin Exp Pathol; 2019; 12(10):3685-3699. PubMed ID: 31933757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(8):e0181615. PubMed ID: 28767665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
    Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
    Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
    Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
    Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weighted Gene Co-expression Network Analysis Identifies CALD1 as a Biomarker Related to M2 Macrophages Infiltration in Stage III and IV Mismatch Repair-Proficient Colorectal Carcinoma.
    Zheng H; Bai Y; Wang J; Chen S; Zhang J; Zhu J; Liu Y; Wang X
    Front Mol Biosci; 2021; 8():649363. PubMed ID: 33996905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
    Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
    J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.